Finally, we picked the rest of the newest medicines approved by the FDA this year. Previous posts included information on medications treating different types of cancer, Lou Gehrig’s disease, Crohn’s disease, CLN2 disease, rheumatoid arthritis and psoriatic arthritis, plaque psoriasis, osteoporosis, allergic conjunctivitis, glioma, tardive dyskinesia, and a new painkiller.
The newest medicines of the year (continued)
One of of the newest medicines is Austedo (deutetrabenazine), that comes in tablets and treats chorea associated with Huntington’s disease.
Huntington’s disease causes the progressive breakdown of nerve cells in the brain. Finally, it may cause serious movement, thinking and psychiatric disorders.
Unfortunately, medications help only in managing the symptoms.
First of all, Bavencio (avelumab) injections treat patients with metastatic Merkel cell carcinoma. Also, this medication is used for urothelial carcinoma treatment.
Dupixent (dupilumab) also comes in injections. It treats moderate to severe atopic dermatitis in adults.
Atopic dermatitis is a common skin disease, also known as eczema. Dry and scaly patches on the skin along with severe itching are the main symptoms of the disease. So, it is extremely important to reduce them.
Ocrevus (ocrelizumab) injections treat all forms of multiple sclerosis.
Symproic (naldemedine) tablets were made to treat opioid-induced constipation.
Xadago (safinamide) tablets for Parkinson’s disease help patients overcome certain periods. Particularly, they reduce tremor and difficulty walking. Actually, it is an add-on treatment, but Parkinson’s disease cannot be totally cured anyway.
This condition usually hits people over age 60. While dopamine producing cells in the brain die, patients start to experience difficulties doing the simplest things, such as writing, eating, or shaving.
Unfortunately, people with severe liver problems cannot take the drug. In addition, it has some side effects. For example, some patients may experience nausea and sleeping problems.
Zejula (niraparib) capsules are a maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.